We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Endorses Risk-Benefit of AcelRX Opioid
Advisory Committee Endorses Risk-Benefit of AcelRX Opioid
An FDA advisory panel voted 10-3 Friday that the benefits of AcelRX’s synthetic opioid candidate Dsuvia (sufentanil) outweigh its risks for treating moderate-to-severe acute pain.